Q1. What are accelerated approval pathways?
They are regulatory routes that allow earlier approval or review for serious conditions when early evidence suggests a meaningful benefit.
Q2. How is FDA accelerated approval different from Priority Review?
Accelerated Approval can permit approval based on a surrogate endpoint, while Priority Review only shortens the review clock for an application.
Q3. What is the role of confirmatory trials?
Confirmatory trials verify whether the expected clinical benefit is real; they are mandatory after Accelerated Approval.
Q4. Are Fast Track and Breakthrough Therapy the same as Accelerated Approval?
No. Fast Track and Breakthrough Therapy are development and review designations, while Accelerated Approval is an approval mechanism.
Q5. What is conditional approval in the EMA system?
It is a pathway that allows earlier authorization when benefits outweigh risks, and that allows additional data to be generated after approval.
Q6. Why are oncology and rare disease programs often accelerated?
They often involve serious disease, limited treatment options, and urgent unmet medical needs.
Q7. Do biologics use accelerated pathways, too?
Yes. Biologics can qualify when they address serious conditions and meet the relevant evidentiary criteria.
Q8. What should sponsor plan for early?
They should plan endpoint strategy, regional regulatory alignment, confirmatory studies, and post-approval compliance from the outset.
Comments are closed